Advanced company searchLink opens in new window

AXALBION THERAPEUTICS LIMITED

Company number 13224059

Filter by category

Filter by category


Confirmation statement filters

Company Results (links open in a new window)
Date (document was filed at Companies House) Type Description (of the document filed at Companies House) View / Download (PDF file, link opens in new window)
03 Nov 2021 CS01 Confirmation statement made on 3 November 2021 with updates
03 Jun 2021 AA01 Current accounting period shortened from 28 February 2022 to 31 December 2021
22 Apr 2021 PSC07 Cessation of Ashley Arthur Woodcock as a person with significant control on 16 March 2021
14 Apr 2021 AP01 Appointment of Michael Kitt as a director on 31 March 2021
12 Apr 2021 RESOLUTIONS Resolutions
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES10 ‐ Resolution of allotment of securities
03 Apr 2021 RESOLUTIONS Resolutions
  • RES10 ‐ Resolution of allotment of securities
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES01 ‐ Resolution of adoption of Articles of Association
03 Apr 2021 MA Memorandum and Articles of Association
26 Mar 2021 AP01 Appointment of Paul Hartley Glyer as a director on 16 March 2021
25 Mar 2021 AP01 Appointment of Mr Adrian Ivery Field as a director on 16 March 2021
25 Mar 2021 AP01 Appointment of Marc-Henry Peppo Jules Rochat as a director on 16 March 2021
25 Mar 2021 SH01 Statement of capital following an allotment of shares on 16 March 2021
  • GBP 716,715
25 Mar 2021 PSC01 Notification of Jonathan Paul Moulton as a person with significant control on 16 March 2021
25 Mar 2021 AP01 Appointment of Peter Vitins as a director on 16 March 2021
24 Feb 2021 NEWINC Incorporation
  • MODEL ARTICLES ‐ Model articles adopted

Statement of capital on 2021-02-24
  • GBP 1